Breakthrough research shows that stem cell genes can be edited in living systems
New research led by Harvard scientist Amy Wagers has demonstrated that gene-editing machinery can be delivered straight to stem cells where they live, rather than in a dish. Published in Cell Reports, the findings have major implications for biotechnology research and the development of therapeutics for genetic diseases.
“If you want to change a genome to correct a disease-causing gene mutation, you have to change it in the relevant stem cells,” said Wagers, the Forst Family Professor of Stem Cell and Regenerative Biology. “If you don’t change the stem cells, whatever cells you do fix may eventually be replaced with diseased cells fairly quickly. If you do fix the stem cells, they will create healthy cells that can eventually replace the diseased cells.”
But fixing stem cells is harder than it sounds. The way it works now, stem cells have to be extracted, kept alive and healthy, genetically altered, then put back in the patient’s body. The process is disruptive for the cells, which may ultimately be rejected or fail to engraft back into the patient.
Each type of stem cell lives in its own “niche,” well-protected in hard-to-reach areas such as bone marrow. “When you take stem cells out of the body, you take them out of the very complex environment that nourishes and sustains them, and they kind of go into shock,” Wagers said. “Isolating cells changes them. Transplanting cells changes them. Making genetic changes without having to do that would preserve the regulatory interactions of the cells — that’s what we wanted to do.”
Transport by virus
Wagers’ group used an adeno-associated virus (AAV) that infects human (and mouse) cells—but does not cause disease—as a transport vehicle. Building on their earlier work in mice with Duchenne muscular dystrophy, Wagers and her colleagues created various AAV packages to deliver gene-editing cargo into several different types of skin, blood, and muscle stem and progenitor cells.
“This was a true collaboration between labs specializing in several different organs,” said Jill Goldstein, a postdoctoral fellow in the Wagers lab and co-first author of the study. “We set up experiments in our organs of interest, analyzed them, compared notes, and made adjustments in a kind of scientific assembly line. None of us could have done it alone — it takes a lot of hands, and the team approach made it really fun.”
To test whether their AAV complexes managed to deliver, the researchers used mice that act as so-called reporter systems via a “reporter” gene that is normally silenced but can be turned on by gene editing. When the reporter gene is activated, the cell turns bright, fluorescent red.
Up to 60 percent effective
The researchers observed that in skeletal muscle, up to 60 percent of the stem cells turned fluorescent red. In cells that give rise to different types of skin cells, up to 27 percent of the cells turned red. Up to 38 percent of the stem cells in bone marrow (which make blood) were changed. That might seem low, but blood turns over so quickly that in some cases even a single healthy stem cell may be sufficient to rescue a defect.
“So far, the concept of delivering healthy genes to stem cells using AAV hasn’t been practical because these cells divide so quickly in living systems — so the delivered genes will be diluted from the cells rapidly,” said Sharif Tabebordbar, an alumnus of Harvard’s Department of Stem Cell and Regenerative biology and now a postdoctoral fellow at the Broad Institute. “Our study demonstrates that we can permanently modify the genome of stem cells, and therefore their progenies, in their normal anatomical niche. There is a lot of potential to take this approach forward and develop more durable therapies for different forms of genetic diseases. That includes different forms of muscular dystrophy, where tissue regeneration is such an important factor.”
“We looked at the skin of these AAV-transduced mice from the Wagers lab, and were pleased to see that many dermal cells were successfully edited as well,” said Ya-Chieh Hsu, Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology. “Those included cells that give rise to dermal adipocytes, and cells that help regulate other stem cells in the skin. We’ve always needed a tool that lets us manipulate dermal cells in vivo rapidly — so for us, this is like a dream come true.”
‘Things might start to move very quickly’
Delivering a gene therapy directly into a living system has been a barrier for biotech companies trying to develop therapies for diseases like spinal muscular atrophy.
“This is a really important resource for the community for two reasons,” Wagers said. “First, it changes the way we can study stem cells in the body. The AAV approach lets researchers investigate the importance of different genes for stem cells in their native environment, much more quickly than ever before. Because the delivery system is so robust, it can also be used to target genes that affect many different tissues.
“Secondly, it’s an important step toward developing effective gene therapies. The approach we developed gets around all the problems you introduce by taking stem cells out of a body and allows you to correct a genome permanently. AAVs are already being used in the clinic for gene therapy, so things might start to move very quickly in this area.”
Learn more: Editing genes at the source
The Latest on: Gene therapy
via Google News
The Latest on: Gene therapy
- Faced With Paying For Pricey Gene-Therapy Treatments, Insurers Start Thinking Outside The Boxon September 6, 2019 at 9:34 am
The expensive new therapies can be life-changing, but working out how to pay for them has become a pain point for the health industry. “Employers are saying, ‘I just can’t afford it ...
- Cancer Gene Therapy Market Growth Opportunities, Trends by Manufacturers, Regions, Application and Forecast to 2024on September 6, 2019 at 8:24 am
Sep 06, 2019 (AmericaNewsHour) -- The Cancer Gene Therapy Market report offers detailed competitive landscape of the global market. It includes company market share analysis, product portfolio of the ...
- Novartis, Spark gene therapies win a boost with soup-to-nuts Cigna coverageon September 6, 2019 at 8:20 am
A recent controversy over data manipulation during the development of Novartis’ new gene therapy, Zolgensma, has overshadowed another issue pressuring the spinal muscular atrophy (SMA) treatment: its ...
- Gene Therapy Market Size Projected to Increase at a CAGR of 31.5% through 2025on September 6, 2019 at 6:10 am
Sep 06, 2019 (The Expresswire) -- The global gene therapy market size is evaluated at $710 million as of 2018 and is anticipated to grow with a CAGR of 31.5% throughout the forecast period 2019-2025.
- Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatmentson September 6, 2019 at 5:36 am
NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio - Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled "Gene Therapy Treatments Offer Hope ...
- Here’s how insurers are trying to keep million-dollar gene therapy costs downon September 6, 2019 at 12:46 am
Insurance companies are working hard to make highly expensive gene therapies more accessible, as the FDA approves more and more types of life-saving treatments. Continue Reading Below These new ...
- Gene therapy startup Passage Bio raises $110M Series B, its second raise in less than a yearon September 4, 2019 at 1:21 pm
Philadelphia-based novel gene therapy startup Passage Bio says it closed a $110 million Series B round of funding, less than seven months after raising a $115.5 million Series A. The company’s latest ...
- Novartis sees cell, gene therapy reaching up to 15% of sales in midtermon September 4, 2019 at 7:00 am
ZURICH (Reuters) - Novartis (NOVN.S) sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss newspaper reported on ...
- Gene therapy for rare eye disease set to be offered on NHSon September 3, 2019 at 6:08 pm
Patients with a rare inherited eye disorder are set to be able to access a new gene therapy on the NHS which slows down sight loss. Draft NICE guidance recommends the therapy (Luxturna) to treat ...
- Gene therapy developer Gyroscope Therepaeutics raises $60.6Mon September 3, 2019 at 12:51 pm
Gyroscope Therapeutics, a British gene therapy company that has its U.S. headquarters in Ambler, raised $60.6 million in a venture capital financing. The Series B round was led by Syncona Ltd., a ...
via Bing News